Transjugular renal biopsy in high-risk patients: an American case series by Abbott, Kevin C et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
BMC Nephrology
BMC Nephrology  2002,  3 x Research article
Transjugular renal biopsy in high-risk patients: an American case 
series
Kevin C Abbott*1, Franco M Musio1, Ellen M Chung2, Nick N Lomis2, 
John D Lane2 and Christina M Yuan1
Address: 1Nephrology Service, Walter Reed Army Medical Center, Washington, DC and 2Interventional Radiology Service, Walter Reed Army 
Medical Center, Washington, DC
E-mail: Kevin C Abbott* - kevin.abbott@na.amedd.army.mil; Franco M Musio - franco.musio@na.amedd.army.mil; 
Ellen M Chung - emchung21@yahaoo.com; Nick N Lomis - nick.lomis@na.amedd.army.mil; John D Lane - john.lane@na.amedd.army.mil; 
Christina M Yuan - christina.yuan@na.amedd.army.mil
*Corresponding author
Keywords: transjugular renal biopsy, kidney, liver, anticoagulation, horseshoe kidney, renal 
failure
Abstract
Background: In the United States, transjugular renal biopsies using the Quickcore™ side cut
needle system have previously been described primarily for transjugular renal biopsy in patients
with concurrent liver and kidney disease.
Methods: We describe transjugular renal biopsy with the Quickcore™ system in 9 patients with
nephrotic syndrome and contraindications to percutaneous renal biopsy, who underwent biopsy
between 23 October 1996 and 12 April 2001. The most common contraindication was oral
anticoagulation with coumadin (40%). Other contraindications included horseshoe kidney, severe
renal failure, and spontaneous coagulopathy. A 62 cm straight catheter and 60 cm side-cut
Quickcore™ biopsy needle were used to obtain cortical tissue. Packing of the biopsy tract with
Gelfoam™ was used for venographically identified capsular perforation.
Results: Ten procedures were performed on 9 patients with one requiring re-biopsy (5% of all
renal biopsies performed at our institution). There were 9 transjugular renal biopsy and one
combined liver-kidney biopsy. A mean of 4 ± 2 passes were made, with a mean of 3 ± 1 cores
obtained per procedure. Histologic diagnosis was made in 90% of biopsies and in 100% of patients.
Two patients developed transient hydronephrosis associated with gross hematuria; both required
transfusion. Capsular perforation occurred in 90%. One patient died of bacterial sepsis, unrelated
to the biopsy, several days after the procedure.
Conclusions: Transjugular renal biopsy appears to be efficacious in high-risk patients, for whom
the percutaneous approach is contraindicated, including patients on oral anticoagulation. The
transfusion rate in the present study was similar to other American reports using this technique.
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Background
The number of patients who are not suitable candidates
for percutaneous renal biopsy (PRB) may increase in the
future because of increasing prevalence of bleeding dia-
theses, both spontaneous and due to wider use of antico-
agulation for thrombotic disorders and dysrythmias. [1]
The most common indication for renal biopsy in the Unit-
ed States is the nephrotic syndrome. [2] This condition
has been associated with an increased risk of thromboem-
bolism, particularly in patients with membranous neph-
ropathy [3] or systemic lupus erythematosus, [4] and such
patients may thus also require anticoagulation. Several al-
ternative techniques have developed over the last decade
for those who have contraindications to PRB. Of these, the
most widely used are the various methods of endovascu-
lar biopsy. The current status of transjugular renal biopsy
(TJRB) has been reviewed recently. [1] Most reports and
the largest series, in a broad array of settings, have come
from Europe. [5–7] In the United States, the only reports
of experience with TJRB have been in patients with con-
current liver and kidney disease. [8]
Since the seminal report of Mal, et al [5], an even larger
TJRB series has been reported by Cluzel, et al [6]. Four
hundred patients undergoing TJRB were compared to 400
patients undergoing PRB, using the modified Colapinto™
aspiration needle system. Diagnostic tissue adequacy was
95.8%, with a major complication rate of 1%. Although
excellent results were obtained, this technique appears to
require a steep "learning curve," according to the authors.
The endovascular automated side-cut core biopsy sets
such as the Quick-Core™ (Cook, Bloomington, IN) may
allow even higher yields of diagnostic tissue with possibly
less operator-dependence. In addition, biopsy tract em-
bolization to reduce bleeding risk post-biopsy is possible
using this system. So far no American center has reported
results on the use of the Quick-Core™ biopsy set in pa-
tients with contraindications to PRB (other than com-
bined liver and kidney disease) referred for TJRB. We
report our experience with this technique at our institu-
tion from October 1996–April 2001.
Materials and Methods
Data on 9 of 10 patients undergoing TJRB at Walter Reed
Army Medical Center (WRAMC) from 23 October 1996 to
30 April 2001, including demographics, indications, tech-
nical details, and complications, were recorded and ana-
lyzed. The starting date reflects the time at which all TJRB
began to be tracked by both Nephrology and Interven-
tional Radiology at WRAMC. The protocol (WU # 1186)
was submitted to the WRAMC institutional review board
and approved in May 1997. Seven patients with biopsies
performed between October 1996 and May 1997 were an-
alyzed retrospectively. Data on 3 of 4 subsequent biopsies
were obtained prospectively. (One patient declined con-
sent, and thus no clinical data is available regarding the
biopsy). Six different interventional radiologists per-
formed the biopsies over the course of the study.
All biopsies were performed in the interventional radiolo-
gy suite with biplane or single-plane anteroposterior and
lateral fluoroscopic capabilities. Biopsy was performed
only if patient blood pressure was <140/90 mm Hg. In
most patients, a previous abdominal sonogram was avail-
able. Prothrombin time, partial thromboplastin time, INR
(where indicated), platelet count, and serum creatinine
level were obtained before each procedure. No patient
had significant thrombocytopenia. Management of pa-
tients on anticoagulation was per the recommendations
of Kearon, et al [9]. No patient was given fresh frozen plas-
ma or cryoprecipitate, before or after the procedure. No
bleeding times were performed. Patients were given pre-
biopsy DDAVP or estrogen if the serum creatinine was ≥  3
mg/dl or the creatinine clearance by the Cockcroft-Gault
formula was ≤  30 cc/min, as previously described (N = 5)
[10]. No patients were dialysis-dependent, either acutely
or chronically.
All biopsies were performed with the transjugular Quick-
Core™ needle biopsy system (Cook, Bloomington, IN),
which consists of a 7 F, 50.5-cm transjugular sheath with
a 14 G inner-stiffening cannula; a 5 F, 80-cm multipur-
pose curved catheter; and a 60-cm biopsy needle with a 2-
cm throw length. Biopsy was performed preferentially on
the right kidney because the right renal vein is shorter
than the left, and provides a better angle for access to the
kidney. Biopsy specimens were obtained with the 60-cm
biopsy needle oriented in a posterolateral direction to
avoid inadvertent puncture of the colon.
The right neck was prepared and draped in sterile fashion.
A guide wire was advanced through the distal lumen of 9F
catheter into the inferior vena cava and the 9F catheter re-
moved. This was replaced with a 14F short vascular
sheath.
For the one patient who underwent a combined liver and
kidney biopsy, a 5F angled multipurpose catheter was ad-
vanced through this sheath, over a wire, to the inferior
vena cava and used to selectively cannulate the right he-
patic vein. The catheter was passed distally into the hepat-
ic vein. Hepatic wedge venography with carbon dioxide
(because of the patient's renal insufficiency) was per-
formed. An Amplatz™ (Cook, Bloomington, IN) wire was
then placed and the catheter removed. Over the Amplatz™
wire the Cook Quick-Core™ biopsy sheath was advanced
without difficulty into the proximal hepatic vein. The wire
was removed and a 20-gauge Quick-Core™ biopsy needle
used to obtain core biopsy specimens. The sheath was
then removed over a wire.BMC Nephrology 2002, 3 http://www.biomedcentral.com/1471-2369/3/5
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For patients undergoing renal biopsy (either combined or
separate), after cannulation of the right internal jugular
vein, the multipurpose catheter was advanced and used to
engage the right renal vein. Over a hydrophilic wire, the
catheter was advanced until it wedged within the right
lower pole of the kidney. This was verified by injection of
3 cc of contrast material. The guiding sheath was then an-
gled posteriorly (to avoid inadvertent colonic puncture)
and biopsy specimens obtained with the 18-gauge Quick
Core™ needle as described for liver biopsy. Extravasation
of contrast post venography through the sheath was taken
as evidence of capsular perforation. If extravasation of
contrast was seen, the tract was selected using a Terumo
wire and the small catheter included in the liver access set.
A Gelfoam™ (Pharmacia, Upjohn Inc., Peapack, New Jer-
sey) pledget was then placed at the far aspect of this tract
near the capsule until no further extravasation of contrast
was demonstrated. The collecting system was assessed for
free drainage of contrast or development of caliectasis. No
further filling of the tract was demonstrated after the em-
bolization. All biopsy devices were then removed. The
catheter, its stiffeners, and sheath were all removed and
hemostasis obtained with manual compression. For pa-
tients previously on oral coumadin, depending on the in-
dication (as per Kearon, et al [9]), intravenous heparin
was restarted in as soon as two hours (no bolus, mainte-
nance infusion only). Oral coumadin was generally start-
ed the same night.
For the patient with the horseshoe kidney, access to the
right internal jugular vein and inferior vena cava was as
above. A wedged venogram with a very small amount of
contrast material demonstrated some cortical staining.
The Rosen guide wire was reintroduced and the catheter
was exchanged for the 8-French vascular sheath with a
stiffener. The guide wire was removed, and a small
amount of contrast material again demonstrated intravas-
cular placement of the sheath.
There was transgression of the collecting system with the
first biopsy specimen; however, there was no filling of the
collecting system following the introduction of a single
pledget of GelfoamTM. After completion of the proce-
dure, there was no evidence of intraluminal filling defect
within the right renal collecting system (i.e., no significant
thrombus within the collecting system). The extracapsular
contrast collection was approximately 2 cm ×  2 cm and
was not observed to expand over the final 10 minutes of
the procedure.
The length of core samples obtained was generally 10–14
mm, maximally 18–20 mm. Tissue for hematoxylin and
eosin, periodic acid-Schiff and other special stains, as well
as electron microscopy was fixed in 2% glutaraldehyde so-
lution. Tissue for immunofluorescence was preserved in
Michel's Fixative (Poly Scientific, Bay Shore, NY). Paraffin
sections were used for light microscopy. Specimens were
processed for immunofluorescence and electron micros-
copy in standard fashion. All specimens were examined
by a single nephropathologist at the Armed Forces Insti-
tute of Pathology.
After biopsy, outpatients were admitted to a 23-hour re-
covery unit, and remained in bed for at least 12 hours,
with frequent observation of vital signs. Hematocrit was
assessed 4–6 hours post biopsy. Serial urines were collect-
ed to assess for hematuria. All but two of the patients in
whom TJRB was performed as an outpatient procedure
were discharged the next day. The patient found to have
systemic amyloidosis was already an inpatient for clinical
reasons.
Results
Patient characteristics, contraindications to conventional
PRB, and outcomes are shown in Table 1 (see additional
file 1). Ten biopsies were performed in 9 patients (1 pa-
tient had a successful repeat TJRB one month after the first
attempt yielded inadequate tissue). No patient required
open surgical biopsy. Mean age was 58 ± 21 years. Six were
Caucasian; 2 African-American, and 1 Asian-American.
There were 4 males and 5 females.
Four of 9 patients had substantial renal failure, i.e., serum
creatinine ≥  3 mg%, which constituted a relative contrain-
dication. No patient was referred for morbid obesity. The
most common contraindication to PRB was bleeding dia-
thesis (5/9), either due to coumadin anticoagulation (2
with history of deep vein thrombosis, 1 with history of
pulmonary embolus, and 1 with anti-cardiolipin anti-
body syndrome with associated deep vein thrombosis) or
spontaneous coagulopathy. No patient had a platelet
count < 100,000 cells/mm3. Mean INR (international
normalized ratio) at the time of biopsy in these 5 patients
was 1.4 ± 0.3. Two patients proved to have membranous
glomerulonephritis, and were on coumadin prior to biop-
sy. Proteinuria had preceded thromboembolic events in
these patients.
Tissue was adequate for diagnosis in 9/10 biopsies, and in
all patients (due to successful re-biopsy). The mean
number of passes was 4 ± 2, yielding 3 ± 1 biopsy cores,
with a mean glomerular number of 9 ± 8. Capsular perfo-
ration occurred in 9/10 biopsies, but gross hematuria oc-
curred in 6/10 biopsies-1 of which occurred in the only
patient without capsular perforation. The biopsy that pro-
duced inadequate tissue was the only one in which capsu-
lar perforation did not occur. The hematocrit declined ≥  4
% after biopsy in 3/10 biopsies. Transfusion was needed
in only 2 patients; these two also developed hydroneph-
rosis due to collecting system bleeding, which resolvedBMC Nephrology 2002, 3 http://www.biomedcentral.com/1471-2369/3/5
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without further intervention. One had horseshoe kidney,
and the other was on coumadin for anti-cardiolipin anti-
body syndrome. She resumed intravenous heparin and
coumadin the day of the biopsy due to high thrombosis
risk. Only one other of the 4 patients on oral anticoagu-
lants had intravenous heparin restarted the same day; the
other two began oral coumadin that night. One patient
died of bacterial sepsis (presumed due to line infection)
several days after biopsy (an 88-year-old man with liver
and renal amyloidosis). No patient developed significant
renal failure after the procedure (defined as a serum creat-
inine level elevation ≥  1.5 mg/dl or requirement for dial-
ysis).
Discussion
Recent series have shown that tissue adequacy with TJRB
is excellent (>95%) 5,7 and comparable to PRB [5]. The
tissue adequacy of 90% for procedures and 100% for pa-
tients in our study is comparable to that in other reports.
The mean number of glomeruli obtained by Sam, et al [8]
was higher than in our series. This may be due to their rou-
tine use of pathology review during biopsy, which was not
feasible at our institution.
Biopsy influenced management in all cases, except for Pa-
tient 9, who was diagnosed with amyloidosis, and who
died from sepsis. Subsequent to biopsy, patients 1 and 2
were treated with chlorambucil and methylprednisolone
[11]. Patient 7, who presented with heavy proteinuria and
nephritic urinary sediment, proved to have mesangial lu-
pus nephritis. Without renal biopsy, which excluded dif-
fuse proliferative lupus nephritis, she might have been
reasonably treated empirically with cyclophosphamide
[12]. Patient 8 had minimal change nephropathy. While
this 22-year-old patient might have been treated empiri-
cally with prednisone, his presentation was also consist-
ent with focal segmental glomerulosclerosis, which would
have been treated differently [13].
Although large series of TJRB using the modified Colapin-
to™ aspiration needle system have been reported [5–7],
the largest series on the use of 18-g automated biopsy nee-
dle is that of Sam, et al, [8] which reported on 29 TJRB. In
the series reported by Cluzel, et al [6], 8 of 400 TJRB were
done with Quick Core™ automated systems. They com-
mented that the stiffness of the Quick Core™ system virtu-
ally precludes a left jugular approach, but because of its
thinness, allows deeper placement in the renal parenchy-
ma. The Colapinto™ device appears to require more train-
ing to deploy properly, because of its flexibility and the
requirement for manual aspiration of samples. In a rand-
omized, unblinded study of liver biopsies, the time re-
quired for training, procedure time, and tissue adequacy
were superior for automated biopsies vs. aspiration biop-
sies, with similar complication rates [14]. No such com-
parisons exist for TJRB.
During the same time period as this series, we performed
192 native PRB. There were no laparoscopic or open sur-
gical biopsies. Thus, only 5% of biopsies at WRAMC were
deemed "contraindicated" by the percutaneous approach,
and all were able to be done using TJRB. Therefore, TJRB,
at least in our practice setting, is unlikely to become a
"high-volume" procedure, but despite this, is able to be ef-
fectively and safely done by interventional radiologists
with transjugular liver biopsy experience and equipment,
i.e., the Quick Core™ automated system. Transjugular liver
biopsy is generally a more common procedure, and was
performed 12–14 times a year at our institution during
the time of the study.
In our series, 5/9 patients had a coagulopathy, either
spontaneous or due to coumadin. Two (22%) had an INR
> 1.5 at the time of biopsy, in comparison to 39% in the
series of Sam, et al [8], whose patients had advanced
chronic liver disease. They attempted to correct coagulop-
athy in all patients, although the details of correction were
not specified. In contrast, because of the different etiology
of coagulopathy in most of our patients, we performed
TJRB through a heparin window as per Kearon, et al [9].
Theoretically, the same could be done for PRB, although
bleeding risk would typically persist for six weeks, and the
percutaneous tract would be associated with a greater
bleeding risk than with TJRB, even given capsular perfora-
tion.
The issue of capsular perforation is also relevant to tissue
adequacy. In animal models, better specimens with more
glomeruli were obtained after unintentional capsular per-
foration, presumably due to more distal positioning of
the biopsy needle [15]. The high rate of capsular perfora-
tion in our study was not associated with a high compli-
cation rate, given the high risk of the population. The
transfusion rate of 20% is lower than the 29% rate of Sam,
et al [8]. The use of a side-cut needle with a shorter (1 cm)
throw and a blunt-tipped end to reduce the risk of capsu-
lar perforation and other organ damage 16 has been suc-
cessful in animal models, but has not been reported in
humans.
Cluzel, et al [6] reported low transfusion rates (about 1%)
after TJRB. However, the population studied is not com-
parable to ours or that of Sam, et al [8]. Possibly the most
common indication for TJRB in the Cluzel study was an
elevated bleeding time, even with a normal creatinine or
absent bleeding history. It was largely on this basis that
76% of the patients in the study were said to have had a
"bleeding abnormality." In many centers, particularly in
the United States, such patients are likely to be treatedBMC Nephrology 2002, 3 http://www.biomedcentral.com/1471-2369/3/5
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with DDAVP or conjugated estrogen before PRB [1]. In
our study, only one patient with a "coagulopathy" re-
quired transfusion. The other transfusion was required by
the patient with a horseshoe kidney, who had no other
risk factors for bleeding, and is, to our knowledge, the first
such patient to undergo TJRB.
The two cases of bleeding-associated hydronephrosis, one
of which was in the patient with horseshoe kidney, were
the result of a communication with the urinary tract. In
the horseshoe kidney, this could have been due to aber-
rant location of the collecting system. In fact, contrast ex-
travasation into the collecting system was observed during
the procedure. In the other case, caliectasis was noted dur-
ing the procedure, which was initially attributed to the
pressure of injection. This patient had been on coumadin
anticoagulation, although the INR at the time of biopsy
was 1.2. She was restarted on heparin and coumadin the
day of the biopsy because of high risk of thrombosis. The
use of Gelfoam™ embolization did not prevent significant
bleeding in these two patients, possibly because the tracts
could not be exactly approximated, or the Gelfoam™
pledget became displaced. It is noteworthy that both
transfusion and Gelfoam™ failure were associated with
urinary tract perforation, because Gelfoam™ embolization
is less likely to be successful in preventing bleeding in this
setting. Gross hematuria, without the need for transfu-
sion, has not been reported specifically as a complication
after TJRB. Therefore, our gross hematuria rate of 60%
cannot be compared with other studies. However, we
speculate that in the process of obtaining a core specimen,
adjacent vessels were disrupted and could have led to in-
troduction of blood into the renal tubules, especially in
patients with disturbed hemostasis.
The one death in our series was due to sepsis in a patient
with systemic amyloidosis, unrelated to the biopsy. The
patient's hematocrit declined only 1.4% post-procedure,
despite a spontaneous coagulopathy.
The generalizability of our series is limited by its small
size. Because none of the patients were obese, no conclu-
sions about the safety of TJRB in obese patients can be
drawn. As technology improves, the cost and complexity
of TJRB is likely to decrease. In fact, the cost of TJRB at "ex-
perienced" institutions is less than twice that of PRB, and
the technique is particularly advantageous in combined
liver-kidney biopsy [5–8]. Given the "user-friendly" char-
acteristics of the Quick Core™ transjugular biopsy set, in-
terventional radiologists throughout the world with
transjugular liver biopsy experience can reasonably apply
this technique. The most common contraindications to
PRB are likely to be maintenance anticoagulation or
bleeding diathesis (due in some cases to acute or chronic
renal failure), perhaps followed by congenital abnormali-
ties. The present study shows that the transjugular tech-
nique can obtain diagnostic renal tissue in these
circumstances. The safety of this procedure in high-risk
populations is still uncertain due to the small numbers of
patients studied with the equipment used in the present
study. Due to the low volume of procedures, it is unusual
to find institutions with experience in multiple methods
of high-risk renal biopsy (ie, both TJRB and Laparoscopic
renal biopsy). Because TJRB is considered only when con-
ventional PRB is contraindicated, comparison with PRB is
not possible. Future studies are suggested to determine the
best method of embolizing the biopsy tract in TJRB, given
the results of the present study.
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